Ambareesh Baliga of Edelweiss Financial Services told CNBC-TV18, "GlaxoSmithKline Pharmaceuticals is going to be arbitrage opportunity where one will possibly get about 10-11 percent arbitrage gain. We have been positive on Sun Pharmaceutical Industries and Lupin for quite a while, we continue holding that."
"Dishman Pharmaceuticals & Chemicals could be a performer in the pharma pack where we have seen that it corrected to levels of about Rs 55-60 from Rs 130-140 and now it is again going back. Possibly we should see levels of about Rs 120 for that stock," he added.
"I will hold GSK, because this is not complete delisting. So I think there is decent amount of upside even from here and I suppose most of the large holders, the institutions may not really tender. So from that point of view it will be a good arbitrage opportunity."
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!